Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis
Open Access
- 20 July 2014
- journal article
- research article
- Published by Hindawi Limited in Mediators of Inflammation
- Vol. 2014, 1-11
Abstract
Background. The therapeutic management of psoriasis includes conventional treatments as well as the new generation of highly effective TNF-αinhibitors. However, psoriasis has proven to be a complex therapeutic challenge and treatment failures are not uncommon. Thus, laboratory biomarkers of disease progression/therapeutic efficacy may greatly help in the clinical management of psoriasis.Aims. To identify laboratory biomarkers for clinical management and therapeutic monitoring of psoriasis.Methods. An observational study performed on 59 patients, presenting moderate to severe psoriasis, undergoing treatment with anti-TNF-αagents (etanercept, adalimumab, and infliximab). Soluble and cellular immune/inflammatory parameters were assessed at baseline and after 12 and 24 weeks of treatment.Results. Clinical efficacy was achieved in 88% of the subjects at 12 weeks, reaching 90% after 24 weeks. IL-6 and IL-22, which were elevated at baseline, were significantly reduced, in association with a significant decrease of CLA+ T cells and an increase of Treg lymphocytes. T, B, and NK cell subsets and T cell response to recall antigens did not show any evidence of immune suppression.Conclusions. Immune/inflammatory parameters including IL-6 and IL-22, CLA+ T cells, and Treg lymphocytes may prove to be valuable laboratory tools for the clinical and therapeutic monitoring of psoriasis.Keywords
This publication has 59 references indexed in Scilit:
- Altered Bone Biology in Psoriatic ArthritisCurrent Rheumatology Reports, 2012
- New Insights in the Immunologic Basis of PsoriasisSeminars in Cutaneous Medicine and Surgery, 2010
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009
- Genome-wide association scan yields new insights into the immunopathogenesis of psoriasisGenes & Immunity, 2009
- Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic CellsJournal of Investigative Dermatology, 2009
- Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathwaysBritish Journal of Dermatology, 2008
- A rush to judgment on Th17Journal of Experimental Medicine, 2008
- Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsesJournal of Experimental Medicine, 2007
- Development, cytokine profile and function of human interleukin 17–producing helper T cellsNature Immunology, 2007